Fig. 7: Emerging BLU-222 clinical data demonstrate early evidence of activity as monotherapy or in combination with ribociclib + ET in patients with breast cancer.

a A CT scan demonstrates a 43% reduction in measurable disease in the liver of a patient with HR+ breast cancer after 8 weeks of treatment with BLU-222 monotherapy (400 mg BID) (patient 1). b A CT scan demonstrates loss of measurable disease in the liver after 16 weeks of treatment with BLU-222 (400 mg BID) + ribociclib (400 mg QD) + fulvestrant in a patient with HR+ breast cancer (patient 2). c Representative IHC images of baseline and on-treatment tumor biopsy samples from patient two responding to treatment with BLU-222+ribociclib+fulvestrant stained with antibodies against pRb S807/811 and Ki67. d Longitudinal ctDNA tumor fraction and variant allele frequency in patient 2 responding to treatment with BLU-222+ribociclib+fulvestrant.